We report a comprehensive evaluation of the toxin B (TcdB) vaccine adjuvanted with a dual Toll-like receptor ligand liposome adjuvant for infection (CDI). The vaccine completely protected mice from a lethal infection. Compared to alum adjuvanted TcdB, it generated functionally superior systemic antibodies and supported strong memory B cell and gut IgA responses. This pharmaceutically acceptable adjuvant platform holds promise for developing a next-generation CDI vaccine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623652 | PMC |
| http://dx.doi.org/10.1101/2024.11.25.625229 | DOI Listing |
Publication Analysis
Top Keywords
tcdb vaccine
8
vaccine adjuvanted
8
cdi vaccine
8
enhanced immunogenicity
4
immunogenicity tcdb
4
vaccine
4
adjuvanted synthetic
4
synthetic dual-tlr
4
dual-tlr ligand
4
ligand adjuvant
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!